Mira Precision Health is rolling out a new version of a DPYD pharmacogenomic test designed to help cancer patients avoid severe toxicities from widely used chemotherapies, initially targeting large hospital systems in the US.

David Kerr is an internationally recognized leader in colorectal cancer research, clinical trials, and cancer systems innovation. He is Professor of Cancer Medicine at the University of Oxford and has played a central role in shaping modern gastrointestinal oncology.

Mira Precision Health today announced the official U.S. launch of ToxNav^® Advantage^™, a clinically validated pharmacogenomic assay designed to identify cancer patients at increased risk of severe or potentially life-threatening toxicities from fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and capecitabine (XELODA^®).